Farallon Partners Group Files 13G, Discloses >5% Stake in BridgeBio Pharma

BridgeBio Pharma (BBIO) saw a notable ownership disclosure on May 29, 2026 when a consortium of Farallon‑related entities—Farallon Partners, L.L.C.; Farallon Capital Partners, L.P.; Farallon Capital Institutional Partners series; Farallon Capital Offshore Investors II, L.P.; Farallon Capital (AM) Investors, L.P.; Farallon Institutional (GP) V, L.L.C.; Four Crossings Institutional Partners V, L.P.; Farallon F5 (GP), L.L.C.; and Farallon Healthcare Partners (GP), L.L.C.—filed a joint Schedule 13G. Hannah E. Dunn signed on behalf of each partnership as Managing Member, Manager, or General Partner and also acted as attorney‑in‑fact for several individual shareholders, consolidating the filing into a single acquisition statement.

The filing, made pursuant to Section 240.13d‑1(k) of the Securities Exchange Act, confirms that the group meets the passive‑institutional threshold of over 5% of BBIO’s outstanding shares. While the filing does not disclose the exact share count or percentage, the designation as a qualified institutional investor signals that Farallon views BridgeBio as a long‑term, value‑oriented investment rather than an activist stake.

For shareholders, the disclosure is a routine compliance requirement but also a barometer of institutional sentiment. BridgeBio’s stock is currently trading at $66.26, down 3.20% on the day, with a 52‑week range position of roughly 65% and an RSI of 48, suggesting the stock is near the midpoint of its recent price action. Despite the dip, the new stake may be read as a vote of confidence in the company’s pipeline and its positioning within the competitive biotech landscape.

The filing notes that each party is responsible for timely amendments to its own information, but will not be held accountable for inaccuracies in others’ disclosures unless they possess knowledge of such errors. This collaborative approach streamlines reporting while maintaining regulatory compliance.